Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowIn his second month as president of Eli Lilly and Co., John Lechleiter has ordered a reorganization to streamline the Indianapolis pharmaceutical maker.
The changes will eliminate management layers and clarify roles and responsibilities in order to speed decision-making, Lechleiter said in a statement.
Lilly spokesman Phil Belt the reorganization will result in few, if any, layoffs.
The reorganization stretches across several units.
-Lilly Research Laboratories is being restructured to combine global regulatory, medical and patient safety information.
-Within International Operations, European operations has been boiled down from four to two areas of responsibility: European mid-size, and central and eastern Europe; and Africa, Middle East and Commonwealth of Independent States, which are 10 countries formerly within the Soviet bloc.
-U.S. operations will shrink from four division vice president positions to two focusing on physicians and institutions, such as hospitals and third-party payers.
-Global marketing and sales also is streamlining operations.
Lechleiter replaced Sidney Taurel, who retired, on April 1.
Lilly shares fell 2 cents this morning to trade at $48.94.
Please enable JavaScript to view this content.